Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia.
The development of the Cre recombinase-controlled (Cre/LoxP) technique allows the manipulation of specific tumorigenic genes, temporarily and spatially. Our original intention of this study was to investigate the role of Kras and p53 in the development of urinary bladder cancer. First, to validate the effect of intravesical delivery on Cre recombination (Adeno-Cre), we examined activity and expression of β-galactosidase in the bladder of control ROSA transgenic mice. The results confirmed specific recombination as evidenced by β-galactosidase activity in the bladder urothelium of these mice. Then, we administered the same adenovirus into the bladder of double transgenic Kras(LSLG12D/+). p53(fl/fl) mice. The virus solution was held in place by a distal urethral retention suture for 2 hours. To our surprise, there was a rapid development of a spindle-cell tumor with sarcoma characteristics near the suture site, within the pelvic area but outside the urinary track. Since we did not see any detectable β-galactosidase in the area outside of the bladder in the validating (control) experiment, we interpreted that this sarcoma formation was likely due to transduction by Adeno-Cre in the soft tissue of the suture site. To avoid the loss of skin integrity associated with the retention suture, we transitioned to an alternative technique without suture to retain the Adeno-Cre into the bladder cavity. Interestingly, although multiple Adeno-Cre treatments were applied, only urothelial hyperplasia but not carcinogenesis was observed in the subsequent experiments of up to 6 months. In conclusion, we observed that the simultaneous inactivation of p53 and activation of Kras induces quick formation of spindle-cell sarcoma in the soft tissues adjacent to the bladder but slow formation of urothelial hyperplasia inside the bladder. These results strongly suggest that the effect of oncogene regulation to produce either hyperplasia or carcinogenesis greatly depends on the tissue type.
Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America ; University of Colorado Cancer Center, Aurora, Colorado, United States of America.
Xiaoping
X
Yang
Francisco G
FG
La Rosa
Elizabeth Erin
EE
Genova
Kendra
K
Huber
Jerome
J
Schaack
James
J
Degregori
Natalie J
NJ
Serkova
Yuan
Y
Li
Lih-Jen
LJ
Su
Elizabeth
E
Kessler
Thomas W
TW
Flaig
D000256:Adenoviridae / Q000378:metabolism; D000818:Animals; D001947:Breeding; D005260:Female; D005455:Fluorescent Antibody Technique; D005838:Genotype; D006965:Hyperplasia; D019426:Integrases / Q000378:metabolism; D007633:Keratins / Q000378:metabolism; D008279:Magnetic Resonance Imaging; D051379:Mice; D008822:Mice, Transgenic; D009928:Organ Specificity; D016283:Proto-Oncogene Proteins p21(ras) / Q000378:metabolism*; D022661:RNA, Untranslated / Q000235:genetics; D015203:Reproducibility of Results; D012509:Sarcoma / Q000378:metabolism* / Q000473:pathology*; D013194:Staining and Labeling; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D001743:Urinary Bladder / Q000473:pathology*; D019459:Urothelium / Q000473:pathology*; D001616:beta-Galactosidase / Q000378:metabolism
C110853:Gt(ROSA)26Sor non-coding RNA, mouse; D022661:RNA, Untranslated; D016159:Tumor Suppressor Protein p53; D007633:Keratins; C045073:Cre recombinase; D019426:Integrases; D001616:beta-Galactosidase; C495971:Hras protein, mouse; D016283:Proto-Oncogene Proteins p21(ras)